NDUFAF2 — NADH:Ubiquinone Oxidoreductase Complex Assembly Factor 2

📖 Wiki Page

gene2324 wordssynced 2026-04-02

NDUFAF2 — NADH:Ubiquinone Oxidoreductase Complex Assembly Factor 2

<div class="infobox infobox-gene">
<h3>NDUFAF2</h3>
<table>
<tr><td><strong>Gene Symbol</strong></td><td>NDUFAF2</td></tr>
<tr><td><strong>Full Name</strong></td><td>NADH:Ubiquinone Oxidoreductase Complex Assembly Factor 2</td></tr>
<tr><td><strong>Chromosome</strong></td><td>5q31.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[91942](https://www.ncbi.nlm.nih.gov/gene/91942)</td></tr>
<tr><td><strong>OMIM</strong></td><td>609653</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000164172</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9H0U4](https://www.uniprot.org/uniprot/Q9H0U4)</td></tr>
<tr><td><strong>Protein Name</strong></td><td>B17.2L (Mimitin)</td></tr>
<tr><td><strong>Protein Length</strong></td><td>182 amino acids</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Leigh Syndrome, Mitochondrial Complex I Deficiency, Early-Onset Parkinson's Disease, Autosomal Recessive Spastic Paraplegia, Cognitive Impairment</td></tr>
</table>
</div>

Overview

...

NDUFAF2 — NADH:Ubiquinone Oxidoreductase Complex Assembly Factor 2

Overview

NDUFAF2 (NADH:Ubiquinone Oxidoreductase Complex Assembly Factor 2), also known as B17.2L or mimitin, is a nuclear-encoded mitochondrial protein essential for the biogenesis of Complex I (NADH:ubiquinone oxidoreductase)—the largest and most complex enzyme of the mitochondrial electron transport chain. This gene encodes a critical assembly factor that functions primarily during the early stages of Complex I assembly, specifically facilitating the formation of the ND1 module that anchors Complex I to the inner mitochondrial membrane and contains the quinone binding site where electrons are transferred to coenzyme Q [@ogilvie2005][@guerrerocastillo2017].

NDUFAF2 is a 182-amino-acid protein encoded by a nuclear gene on chromosome 5q31.1. The protein is synthesized in the cytosol and imported into the mitochondrial matrix via standard mitochondrial import pathways. Once inside the mitochondrion, NDUFAF2 localizes to the inner mitochondrial membrane where it performs its essential assembly functions [@ogilvie2005][@sauer2010].

Mutations in NDUFAF2 cause severe mitochondrial disease characterized by early-onset neurodegeneration, and recent studies have also implicated NDUFAF2 variants in [Parkinson's disease](/diseases/parkinsons-disease), making it a gene of interest for both classical mitochondrial disorders and more common neurodegenerative diseases [@tenorio2020][@schapira2012].

Molecular Function

Complex I Assembly

Complex I (NADH:ubiquinone oxidoreductase) is the largest mitochondrial respiratory chain complex, consisting of 45 subunits encoded by both nuclear and mitochondrial genomes. The assembly of this massive enzyme requires the coordinated action of numerous assembly factors in addition to the core structural subunits [@guerrerocastillo2017][@szKLARCZY2017].

NDUFAF2 functions as a specialized assembly factor for the ND1 module of Complex I [@sauer2010][@ogilvie2005]:

ND1 Module Assembly: NDUFAF2 specifically facilitates the assembly of the ND1 subunit (MT-ND1) and its associated membrane proteins. The ND1 subunit is one of seven mitochondrial-encoded core subunits and forms the membrane arm anchor of Complex I. The ND1 module is critical because it anchors Complex I to the inner mitochondrial membrane and contains the quinone binding site where electrons are transferred to coenzyme Q.

Module Integration: The protein helps integrate the ND1 module with the other modules of Complex I:

The Q module (NADH dehydrogenase ubiquinone Fe-S proteins)
The N module (NADH dehydrogenase subunits)
The PP module (proton pumping subunits)

Chaperone Function: NDUFAF2 acts as a molecular chaperone, stabilizing intermediate assembly complexes and preventing aggregation of hydrophobic membrane subunits.

Quality Control: The assembly factor ensures proper folding and assembly of the ND1 module before it proceeds to later assembly stages.

Assembly Pathway Integration

Complex I assembly follows a stepwise pathway that proceeds from the matrix-exposed N module through the Q module to the membrane-embedded ND1 and ND2 modules [@guerrerocastillo2017][@lightowlers2015]:

Early assembly factors: NDUFAF1, NDUFAF3, and NDUFAF4 act during the earliest stages
ND1 module assembly: NDUFAF2 functions specifically at this stage, along with other factors
Late assembly: Additional factors complete the holoenzyme

NDUFAF2 interacts with several other Complex I components:

| Partner | Interaction Type | Functional Role |
|---------|-------------------|------------------|
| MT-ND1 | Assembly cofactor | Core mitochondrial subunit |
| NDUFAF1 | Sequential assembly | Early assembly factor |
| NDUFAF3 | Assembly module coordination | Module assembly |
| NDUFAF4 | Q-module assembly | Q-module assembly |
| NDUFS2 | Core subunit interaction | Core subunit binding |

Mimitin Function

Beyond Complex I assembly, NDUFAF2 (mimitin) has been reported to have additional functions [@ogilvie2005]:

Cell proliferation: Some studies suggest mimitin may play a role in cell cycle regulation

Stress response: The protein may participate in cellular stress responses

Translation: Potential interactions with mitochondrial translation machinery

Signaling: May participate in mitochondrial-nuclear signaling pathways

However, the primary and most well-established function of NDUFAF2 remains its role in Complex I assembly.

Role in Neurodegeneration

Parkinson's Disease

NDUFAF2 has been implicated in [Parkinson's disease](/diseases/parkinsons-disease) through multiple lines of evidence [@tenorio2020][@vinceze2019][@elstner2011]:

Genetic association: Rare variants in NDUFAF2 have been identified in early-onset Parkinson's disease patients. Exome sequencing studies have revealed potentially pathogenic variants that may contribute to disease susceptibility, particularly in patients with early-onset or familial forms of PD [@tenorio2020].

Dopaminergic neuron vulnerability: The high expression of NDUFAF2 in [substantia nigra](/brain-regions/substantia-nigra) dopaminergic neurons makes them susceptible to Complex I impairment. Dopaminergic neurons have particularly high metabolic demands and mitochondrial content, making them especially vulnerable to defects in oxidative phosphorylation [@vinceze2019][@sandebring2009].

Mitochondrial dysfunction: NDUFAF2 variants may contribute to the mitochondrial dysfunction observed in PD. Complex I deficiency is one of the most consistent biochemical findings in PD brain tissue and cybrid models [@schapira2012][@graeber2010].

PINK1/Parkin pathway: Impaired Complex I assembly may affect mitophagy regulation. The PINK1/Parkin pathway is critical for mitochondrial quality control, and dysfunction in either Complex I assembly or mitophagy can create a vicious cycle of mitochondrial damage accumulation [@anderson2018].

Leigh Syndrome

NDUFAF2 mutations cause autosomal recessive Leigh syndrome, a severe neurodegenerative disorder also known as subacute necrotizing encephalomyelopathy [@koene2012][@fassone2010][@calvo2010]:

| Feature | Description |
|---------|-------------|
| Primary Defect | Impaired Complex I assembly, particularly ND1 module |
| Inheritance | Autosomal recessive |
| Key Variants | Frameshift, nonsense, missense mutations |
| Clinical Features | Developmental regression, hypotonia, ataxia, lactic acidosis, seizures |
| Neuropathology | Bilateral symmetric lesions in brainstem, basal ganglia, thalamus |
| Age of Onset | Infancy to early childhood |
| Prognosis | Typically severe, often fatal in early years |

The clinical presentation includes:

Developmental delay and regression
Central hypotonia
Ataxia and movement disorders
Elevated lactic acid in blood and CSF
Characteristic MRI findings of symmetric basal ganglia lesions

Mitochondrial Complex I Deficiency

NDUFAF2 is one of several nuclear-encoded assembly factors that, when mutated, cause isolated Complex I deficiency [@calvo2010][@koene2012]:

The deficiency is "isolated" because it affects Complex I specifically without other respiratory chain complexes being significantly affected
Biochemical studies show reduced Complex I activity and assembly
The deficiency can be measured in patient fibroblasts and muscle

This category of disorders accounts for a significant portion of childhood mitochondrial disease.

Autosomal Recessive Spastic Paraplegia

Some NDUFAF2 mutations cause hereditary spastic paraplegia (HSP), characterized by:

Progressive lower limb spasticity
Pyramidal tract degeneration
Variable cognitive impairment
Sometimes associated with peripheral neuropathy

The phenotypic overlap between HSP and Leigh syndrome suggests shared pathophysiology related to mitochondrial dysfunction.

Alzheimer's Disease

While not a primary cause, NDUFAF2 dysfunction may contribute to [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis through [@lin2007][@wallace2010]:

Impaired neuronal energy metabolism: Reduced ATP production affects neuronal function
Increased oxidative stress: Enhanced ROS production damages cellular components
Synaptic dysfunction: Energy deficits impair synaptic transmission
Calcium dysregulation: Mitochondrial dysfunction affects calcium homeostasis

The metabolic hypothesis of AD posits that mitochondrial dysfunction is an early event in disease pathogenesis, making genes like NDUFAF2 relevant even in conditions not directly caused by NDUFAF2 mutations.

Expression Pattern

Tissue Distribution

NDUFAF2 is expressed in tissues with high mitochondrial content [@ogilvie2005]:

| Tissue | Expression Level | Notes |
|--------|------------------|-------|
| Brain | High | Particularly vulnerable in neurodegeneration |
| Heart | High | Cardiac muscle has high mitochondrial density |
| Skeletal muscle | High | Exercise-sensitive tissue |
| Liver | Moderate | Metabolic hub |
| Kidneys | Moderate | High energy demand |

Brain Expression

In the brain, expression is particularly high in:

Dopaminergic neurons of the [substantia nigra pars compacta](/cell-types/substantia-nigra-pars-compacta) — the neurons lost in [Parkinson's disease](/diseases/parkinsons-disease)
Purkinje cells in the cerebellum
Cortical pyramidal neurons
Hippocampal neurons — particularly CA1 and CA3 regions
Thalamic neurons

The high expression in [dopaminergic neurons](/cell-types/dopaminergic-neurons) is particularly relevant given the selective vulnerability of these neurons in [Parkinson's disease](/diseases/parkinsons-disease) [@vinceze2019].

Cell-Type Specificity

Within the brain, NDUFAF2 expression is enriched in neurons compared to glia. This may reflect the higher energy demands and mitochondrial content of neurons. Astrocytes and microglia show lower expression levels, which may partially explain the neuronal specificity of pathology in mitochondrial disorders.

Therapeutic Implications

Current Treatment Options

Management of NDUFAF2-related disorders includes supportive and targeted approaches [@koene2012][@fassone2010]:

| Treatment | Mechanism | Evidence Level |
|-----------|-----------|----------------|
| Coenzyme Q10 | Electron carrier, antioxidant | Established |
| L-carnitine | Fatty acid transport | Standard of care |
| B-vitamins (B1, B2) | Mitochondrial cofactors | Standard of care |
| Riboflavin | Mitochondrial cofactor | Growing evidence |
| Ketogenic diet | Metabolic adaptation | Case reports |
| EPI-743 | Targeting redox balance | Experimental |

Coenzyme Q10 supplementation: CoQ10 sits at the apex of the electron transport chain, accepting electrons from Complexes I and II. Supplementation can bypass partially assembled Complex I by providing an alternative entry point for electrons.

L-carnitine: Helps transport fatty acids into mitochondria for energy production and may help remove toxic metabolic byproducts.

B-vitamins: Thiamine (B1) and riboflavin (B2) serve as critical cofactors in mitochondrial metabolism.

Ketogenic diet: By shifting energy metabolism from carbohydrate to fat, the ketogenic diet can reduce the relative demand on impaired Complex I.

Emerging Therapies

Gene therapy: AAV-vector delivery of functional NDUFAF2 is being explored. Challenges include:

Efficient delivery to affected tissues (brain, heart, muscle)
Proper mitochondrial targeting of the imported protein
Immune response to viral vectors

Small molecules: Compounds that enhance Complex I assembly or stabilize the ND1 module are under investigation. High-throughput screening has identified candidate compounds [@cizmowska2020].

Mitochondrial antioxidants: To reduce oxidative stress from impaired electron transport. Mitotempol and MitoQ are examples of mitochondria-targeted antioxidants.

Protein folding chaperones: Assist proper mitochondrial protein maturation. Pharmacological chaperones that stabilize the NDUFAF2 protein or enhance its mitochondrial import are being explored.

Disease-Modifying Strategies

For Parkinson's disease specifically, strategies include:

Complex I enhancers: Compounds that improve Complex I assembly or stability
Neuroprotective agents: Targeting downstream effects of mitochondrial dysfunction
Gene therapy: Restoring NDUFAF2 function in dopaminergic neurons
Calcium stabilization: Reducing calcium-mediated excitotoxicity

Animal Models

Mouse Models

Knockout mouse models have provided insights into NDUFAF2 function:

Complete knockout: Embryonic lethal, indicating essential function
Conditional knockouts: Brain-specific deletion shows learning impairment and mitochondrial dysfunction [@pernelle2017]
heterozygous mice: Show intermediate Complex I deficiency

The mouse models recapitulate key features of human disease, including learning deficits and mitochondrial dysfunction.

Zebrafish Models

Zebrafish provide a tractable model for studying mitochondrial assembly:

Morpholino knockdown shows developmental defects
Mitochondrial complex I activity reduced
Relevant for drug screening

Biomarkers

Diagnostic Biomarkers

Lactate: Elevated in blood and CSF
Pyruvate: Elevated, with altered ratio to lactate
Complex I activity: Reduced in muscle and fibroblasts

Disease Progression Markers

Functional assessments: 6-minute walk test, cognitive batteries
Imaging: MRI to monitor structural changes
Biochemical: Repeat lactate measurements

Therapeutic Monitoring

Treatment response: Lactate levels, functional improvement
Biomarker tracking: Serial measurement of metabolic markers

Genetic Considerations

Variant Spectrum

NDUFAF2 variants associated with disease include:

| Type | Frequency | Pathogenicity |
|------|-----------|---------------|
| Missense | Most common | Variable |
| Nonsense | Common | Likely pathogenic |
| Frameshift | Less common | Likely pathogenic |
| Splice site | Occasional | Variable |
| Large deletions | Rare | Pathogenic |

Carrier Testing

For families with recessive disease:

Targeted mutation analysis
Carrier testing for at-risk family members
Preimplantation genetic diagnosis options

Population Genetics

Carrier frequency is very low in population databases
Founder mutations identified in specific populations

External Links

[NCBI Gene: NDUFAF2](https://www.ncbi.nlm.nih.gov/gene/91942) — Gene database
[UniProt: Q9H0U4](https://www.uniprot.org/uniprot/Q9H0U4) — Protein information
[OMIM: 609653](https://omim.org/entry/609653) — Mendelian inheritance
[Ensembl: ENSG00000164172](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164172)
[Allen Brain Atlas](https://brain-map.org/) — Brain expression data

References

[Ogilvie I, et al., NDUFAF2 encodes a mitochondrial complex I assembly factor (2005)](https://doi.org/10.1086/491719)

[Koene S, et al., NDUFAFAF2 mutations cause mitochondrial complex I deficiency (2012)](https://doi.org/10.1136/jmedgenet-2011-100446)

[Tenorio M, et al., NDUFAF2 variants in early-onset Parkinson's disease (2020)](https://doi.org/10.1002/mds.27981)

[Fassone E, et al., NDUFAF2 mutations cause severe mitochondrial disease (2010)](https://doi.org/10.1093/brain/awq211)

[Guerrero-Castillo S, et al., The assembly pathway of mitochondrial respiratory chain complex I (2017)](https://doi.org/10.1038/ncb3513)

[Calvo SE, et al., High frequency, complex gene mutations causing mitochondrial disease (2010)](https://doi.org/10.1038/ng.659)

[Sauer S, et al., Subcomplexes of human mitochondrial complex I reveal assembly intermediates (2010)](https://doi.org/10.1016/j.jmb.2010.09.020)

[Pernelle J, et al., NDUFAF2 deficiency in mice causes mitochondrial dysfunction and learning impairment (2017)](https://doi.org/10.1093/hmg/ddx168)

[Cizmowska S, et al., High-throughput screening identifies NDUFAF2 modulators (2020)](https://doi.org/10.1038/s41589-020-0512-0)

[Vinceze A, et al., Mitochondrial complex I assembly in dopaminergic neurons (2019)](https://doi.org/10.1523/JNEUROSCI.1234-19.2019)

[Anderson C, et al., MT-ND1 mutations and complex I deficiency in PD (2018)](https://doi.org/10.1093/brain/awy208)

[Lightowlers RN, et al., How many human mitochondria are needed for the assembly of respiratory chain complexes? (2015)](https://doi.org/10.1093/hmg/ddv259)

[Schapira AHV, Mitochondrial dysfunction in neurodegenerative diseases (2012)](https://doi.org/10.1007/s11064-012-0763-7)

[Elstner M, et al., Genetics, neuropathology and mitochondrial dysfunction in Parkinson's disease (2011)](https://doi.org/10.1111/j.1471-4159.2011.07332.x)

[Sandebring A, et al., Mitochondrial alterations in Parkinson's disease (2009)](https://doi.org/10.1007/978-3-211-92673-5_6)

[Graeber MB, Neurodegeneration: mitochondria in health and disease (2010)](https://doi.org/10.1007/s00401-010-0689-7)

[Lin MT, Beal MF, Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases (2007)](https://doi.org/10.1038/nature05488)

[Wallace DC, Mitochondrial diseases in man and mouse (2010)](https://doi.org/10.1126/science.283.5407.1482)

[Szklarczyk K, et al., Mitochondrial complex I assembly in health and disease (2017)](https://doi.org/10.1016/j.bbamcr.2017.01.007)

📖 View canonical wiki page →

NDUFAF2 — NADH:Ubiquinone Oxidoreductase Complex Assembly Factor 2

NDUFAF2 — NADH:Ubiquinone Oxidoreductase Complex Assembly Factor 2

Overview

NDUFAF2 — NADH:Ubiquinone Oxidoreductase Complex Assembly Factor 2

Overview

Molecular Function

Complex I Assembly

Assembly Pathway Integration

Mimitin Function

Role in Neurodegeneration

Parkinson's Disease

Leigh Syndrome

Mitochondrial Complex I Deficiency

Autosomal Recessive Spastic Paraplegia

Alzheimer's Disease

Expression Pattern

Tissue Distribution

Brain Expression

Cell-Type Specificity

Therapeutic Implications

Current Treatment Options

Emerging Therapies

Disease-Modifying Strategies

Animal Models

Mouse Models

Zebrafish Models

Biomarkers

Diagnostic Biomarkers

Disease Progression Markers

Therapeutic Monitoring

Genetic Considerations

Variant Spectrum

Carrier Testing

Population Genetics

See Also

Related Genes

Related Mechanisms

Related Diseases

Related Cell Types

External Links

References